Cargando…
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
BACKGROUND: Metabolic profiling in non-small cell lung cancer (NSCLC) may identify key metabolic vulnerabilities and shows enormous discovery potential. Preclinical studies showed that metabolic rewiring in cancer plays an essential role in modulation of immunotherapy response. However, this situati...
Autores principales: | Kocher, Florian, Amann, Arno, Zimmer, Kai, Geisler, Simon, Fuchs, Dietmar, Pichler, Renate, Wolf, Dominik, Kurz, Katharina, Seeber, Andreas, Pircher, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867793/ https://www.ncbi.nlm.nih.gov/pubmed/33569314 http://dx.doi.org/10.21037/tlcr-20-380 |
Ejemplares similares
-
Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015) -
Indoleamine 2,3-Dioxygenase in Human Hematopoietic Stem Cell Transplantation
por: Jürgens, Birgit, et al.
Publicado: (2010) -
Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022) -
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease
por: Jürgens, Birgit, et al.
Publicado: (2010) -
Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)